Investigation of Novel 1-[1-(5-(substituted)-1,3,4-oxadiozol-2-yl) methyll-3-(4-substituted phenyl)-2-thioxo-2,3-dihydroquinazolin-4(3H)-one analogs as EGFR tyrosine kinase inhibitors.